Literature DB >> 19434744

Retrograde versus antegrade percutaneous aortic balloon valvuloplasty: immediate, short- and long-term outcome at 2 years.

Roberto J Cubeddu1, Hani Jneid, Creighton W Don, Christian F Witzke, Ignacio Cruz-Gonzalez, Rakesh Gupta, Pablo Rengifo-Moreno, Andrew O Maree, Ignacio Inglessis, Igor F Palacios.   

Abstract

BACKGROUND: The short- and long-term vascular risks and hemodynamic benefits of antegrade versus retrograde percutaneous aortic balloon valvuloplasty (PAV) have not been clearly established. With the advent of percutaneous aortic valve replacement strategies, more valvuloplasties are being performed. The antegrade approach may reduce vascular complications, particularly in patients with peripheral vascular disease (PVD). Comparing the clinical efficacy and complications of each technique is warranted.
METHODS: A cohort of 157 consecutive patients undergoing PAV between 2000 and 2006 were included in the study. Of these, 46 (29%) patients underwent antegrade PAV and 111 (71%) retrograde PAV. Choice of vascular approach (antegrade or retrograde) were determined by operator preference. The rate of death, nonfatal vascular complications, and 2-year survival was explored.
RESULTS: The mean age of the study population was 79 years. Patients undergoing antegrade PAV were more likely hypertensive (56% vs. 39%, P = 0.001) with PVD (41% vs. 18%, P = 0.004). Nevertheless, logistic Euroscores were no different between the groups (antegrade 18% vs. retrograde 14%; P = 0.30). Baseline and postprocedural valve areas were also similar. However, patients undergoing antegrade PAV had significantly fewer vascular complications (2% vs. 19%; P = 0.005). Two-year follow-up revealed no significant difference in death (antegrade 81% vs. retrograde 69%; P = 0.16), stroke, congestive heart failure, and surgical aortic valve replacement.
CONCLUSIONS: The hemodynamic benefit of PAV occurs regardless of the selected vascular approach. The antegrade technique results in significantly fewer vascular complications and similar long-term outcomes. Antegrade PAV is feasible and safe, particularly in patients with PVD. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19434744     DOI: 10.1002/ccd.22085

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

1.  First clinical experience of the looped Inoue balloon technique for antegrade percutaneous balloon aortic valvuloplasty.

Authors:  Mariko Yano; Naritatsu Saito; Shin Watanabe; Hirotoshi Watanabe; Ryusuke Nishikawa; Takeshi Fujino; Bingyuan Bao; Erika Yamamoto; Hiroki Watanabe; Kenji Nakatsuma; Masao Imai; Takeru Makiyama; Yoshihito Sakata; Takeshi Kimura; Kanji Inoue
Journal:  Heart Vessels       Date:  2014-07-16       Impact factor: 2.037

2.  Comparing Clinical Outcomes on Oncology Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.

Authors:  Yumeng Song; Yutong Wang; Zuoxiang Wang; Chang Xu; Jingshen Dou; Tingbo Jiang
Journal:  Front Cardiovasc Med       Date:  2022-05-31

3.  Urgent Balloon Aortic Valvuloplasty for Worsening Heart Failure in a Patient with Acute Myocardial Infarction and Critical Aortic Stenosis.

Authors:  Takeshi Yamada; Akihiko Takahashi
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

4.  Patients with small left ventricular size undergoing balloon aortic valvuloplasty have worse intraprocedural outcomes.

Authors:  Creighton Don; Pritha P Gupta; Christian Witzke; Manoj Kesarwani; Roberto J Cubeddu; Ignacio Inglessis; Igor F Palacios
Journal:  Catheter Cardiovasc Interv       Date:  2012-08-23       Impact factor: 2.692

5.  Transcatheter aortic valve implantation in decompensated aortic stenosis within the same hospital admission: early clinical experience.

Authors:  Mahmoud Abdelaziz; Saib Khogali; James M Cotton; Antonella Meralgia; Maciej Matuszewski; Heyman Luckraz
Journal:  Open Heart       Date:  2018-07-25

6.  Mortality after transcatheter aortic valve replacement for aortic stenosis among patients with malignancy: a systematic review and meta-analysis.

Authors:  Muhammad Umer Siddiqui; Omar Yacob; Joey Junarta; Ahmed K Pasha; Farouk Mookadam; Mamas A Mamas; David L Fischman
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.298

7.  Transcatheter aortic valve replacement in patients with severe aortic stenosis and active cancer: a systematic review and meta-analysis.

Authors:  Ahmed Bendary; Ahmed Ramzy; Mohamed Bendary; Mohamed Salem
Journal:  Open Heart       Date:  2020-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.